Dicot Pharma AB Logo

Dicot Pharma AB

Developing next-gen potency drugs for erectile dysfunction and premature ejaculation.

DICOTBT | SPGR

Overview

Corporate Details

ISIN(s):
SE0011178458 (+1 more)
LEI:
549300GX132RSE4OV407
Country:
Sweden
Address:
St Olofsgatan 11A, 753 21 Uppsala
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Dicot Pharma AB is a pharmaceutical company focused on developing the next generation of potency drugs. Its lead drug candidate, LIB-01, is in development for the treatment of erectile dysfunction and premature ejaculation. The company's objective is for LIB-01 to offer significant advantages over existing therapies, including a longer duration of effect, fewer side effects, and efficacy for a broader patient population. Dicot Pharma aims to establish LIB-01 as a first-choice treatment globally, addressing the needs of the over 500 million men worldwide affected by these conditions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dicot Pharma AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Dicot Pharma AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-12 Tullbacken Aktiebolag Other Buy 35,000 40,250.00 SEK
2024-09-10 Amandus Jabin Other Sell 110,000 4,276,800.00 SEK
2024-09-03 Jörgen Larsson Other Other 315,000 N/A
2024-09-02 Patrick Lawlor Other Buy 77,500 1,158,625.00 SEK
2024-09-02 Oskar Hellström Other Buy 75,000 1,121,250.00 SEK
2024-09-02 Martin Walfisz Other Other 2,108,718 442,830.78 SEK
2024-08-31 Bonny Heeren Other Other 5,000,000 550,000.00 SEK
2024-08-30 Per-Anders Hedin Other Other 5,000,000 110,000.00 SEK
2024-08-30 Erik Markus Näsholm Other Other 2,000,000 42,600.00 SEK
2024-08-30 Greger Larsson Other Other 1,600,000 34,080.00 SEK

Peer Companies

Company Country Ticker View
Read Gene Spolka Akcyjna Logo
Develops DNA tests to identify genetic cancer risk for early detection and prevention.
Poland RDG
RELIEF Therapeutics Holding AG Logo
Developing and commercializing novel therapies for rare and ultra-rare diseases.
Switzerland RLF
RYVU Therapeutics S.A. Logo
Clinical-stage drug discovery company developing novel small molecule therapies for oncology.
Poland RVU
SAREUM HOLDINGS PLC Logo
Clinical-stage developer of kinase inhibitors for autoimmune disease & cancer.
United Kingdom SAR
SCANCELL HOLDINGS PLC Logo
Developing therapeutic vaccines and antibodies for cancer and infectious diseases.
United Kingdom SCLP
SCIENCE GROUP PLC Logo
International science & tech consultancy providing advisory, R&D, and product development.
United Kingdom SAG
Selvita S.A. Logo
Preclinical CRO offering integrated drug discovery and development services for life sciences.
Poland SLV
Simris Group AB Logo
Develops novel cyanobacteria-based payloads for Antibody-Drug Conjugates to treat cancer.
Sweden SIMRIS
SKINBIOTHERAPEUTICS PLC Logo
A life science company developing microbiome-based skin health products and supplements.
United Kingdom SBTX
Terranet B Logo
Develops ultra-fast ADAS anti-collision technology for automakers to protect vulnerable road users.
Sweden TERRNT

Talk to a Data Expert

Have a question? We'll get back to you promptly.